Opinion
Published on 12 Jan 2024
Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants
in Pediatric Infectious Diseases
- 1,292 views
- 2 citations